Low-Dose Aspirin, Dipyridamole Cited for Post-Stroke Patients

Article excerpt

Meta-analysis of nearly 340,000 post- stroke patients shows the superior safety of dipyridamole plus aspirin therapy.

The results of the analysis presented to the recent American Heart AssociationEs annual meeting, showed that the therapy was associated with the lowest bleeding risk compared with conventional dose and platelet therapies.

The meta-analysis included data from 50 clinical trials published from 1988 to 2002, with a total of 33,819 patients, to determine bleeding risks associated with antiplatelet agents.

oBleeding risk from inhibiting platelets may significantly worsen the patientEs condition. In post-stroke patients, this is of particular concern because additional bleeding into the brain could have fatal consequenceso said Dr. Victor L. Serebruany, MD, Phd, director of Sinai Thrombosis Center and assistant professor of medicine at Johns Hopkins University, Baltimore. He is lead researcher of this study.

oAlthough significant advancements in antiplatelet therapy have been made over the years, improving the life saving clinical benefits in patients with vascular disease,o he said, ohowever, more aggressive therapy can also be associated with an increased risk of bleeding, which is a major concern among physicians.o

Bleeding rates associated with each antiplatelet agent were categorized by Serebruany with Doctors Alex Malinin and Dr. David Sane of John Hopkins University and Wake Forest University Baptist Medical Center according to minor bleeds, major bleeds, gastrointestinal (GI) bleeds and hemorrhagic stroke.

In this analysis, low dose aspirin and dipyridamole therapy was associated with the lowest bleeding risk. No minor, GI or stroke bleeds were reported with dipyridamole therapy and major bleeds were reported in only 1. …